A 62-year-old man with a 10-year history of rheumatoid arthritis presents with nephrotic syndrome and progressive renal dysfunction. Renal biopsy shows amyloid deposits in the glomeruli. Regarding the classification and pathogenesis of amyloidosis in this patient, all of the following are correct EXCEPT:

Explanation

## Classification and Pathogenesis of Amyloidosis in Chronic Inflammation ### Clinical Scenario Analysis **Key Point:** This patient has **secondary (AA) amyloidosis**, not primary amyloidosis. The 10-year history of rheumatoid arthritis (a chronic inflammatory condition) is the key diagnostic clue. ### Correct Statements (Options 0, 1, 3) | Feature | Details | |---------|----------| | **Type** | Secondary (AA) amyloidosis (option 0 — TRUE) | | **Precursor Protein** | Serum amyloid A (SAA), an acute-phase reactant produced during chronic inflammation | | **Associated Conditions** | RA, TB, chronic osteomyelitis, chronic kidney disease, inflammatory bowel disease (option 1 — TRUE) | | **Renal Manifestation** | Nephrotic syndrome from glomerular amyloid infiltration (option 3 — TRUE) | ### The False Statement (Option 2) **High-Yield:** The amyloid precursor in this case is **serum amyloid A (SAA)**, NOT immunoglobulin light chains. Immunoglobulin light chain amyloidosis (AL amyloidosis) is a **primary** amyloidosis, not secondary. **Mnemonic:** **AL = Primary, AA = Secondary** - **AL amyloidosis**: Light chains (kappa/lambda) from plasma cells; primary (idiopathic or associated with multiple myeloma) - **AA amyloidosis**: Serum Amyloid A; secondary (from chronic inflammation) ### Pathophysiology of AA Amyloidosis ```mermaid flowchart TD A[Chronic Inflammation<br/>RA, TB, Osteomyelitis]:::outcome --> B[Persistent IL-6 and TNF-α]:::outcome B --> C[Hepatic production of<br/>Serum Amyloid A]:::action C --> D[SAA accumulates in blood]:::outcome D --> E[Misfolding and fibril formation]:::action E --> F[Amyloid deposition in<br/>kidney, liver, spleen]:::outcome F --> G[Nephrotic syndrome,<br/>hepatomegaly, organ failure]:::urgent ``` **Clinical Pearl:** AA amyloidosis develops insidiously over years of chronic inflammation. Early detection and aggressive treatment of the underlying inflammatory condition (e.g., TNF inhibitors in RA) can halt or slow progression. ### Distinguishing AL from AA Amyloidosis | Feature | AL Amyloidosis | AA Amyloidosis | |---------|---|---| | **Precursor Protein** | Immunoglobulin light chains (κ or λ) | Serum amyloid A (acute-phase reactant) | | **Classification** | Primary (idiopathic or myeloma-associated) | Secondary (from chronic inflammation) | | **Associated Conditions** | Multiple myeloma, light-chain disease, primary systemic amyloidosis | RA, TB, chronic osteomyelitis, IBD, chronic kidney disease | | **Organ Involvement** | Heart (restrictive cardiomyopathy), PNS, kidney | Kidney (most common), liver, spleen | | **Prognosis** | Poor without treatment; median survival ~5 years | Better if underlying disease controlled | **Warning:** Do not confuse the two types. The presence of a chronic inflammatory condition (RA in this case) strongly points to AA amyloidosis, not AL amyloidosis.